The U.S. Food and Drug Administration on Tuesday approved Eli Lilly’s treatment for early Alzheimer’s, making it the second therapy for slowing progression of the brain-wasting disease that will be available to U.S. patients. The approval for donanemab, to be sold under the brand name Kisunla, followed the recommendations of the agency’s outside experts, who … Read more
The U.S. Food and Drug Administration has delayed its decision on Eli Lilly’s LLY.N experimental treatment for early Alzheimer’s disease and will hold a meeting of outside experts to discuss its safety and efficacy, the company said. The FDA’s decision came as a surprise to company officials and many Alzheimer’s experts, who had expected a … Read more
Some doctors are concerned the drugs’ benefits don’t outweigh the risks (Image: Getty) Dementia experts have raised the alarm over “significant gaps in the data” around Alzheimer’s wonder drugs, amid concerns that they cause some patients’ brains to shrink. The first medication proven to slow the disease’s progression could be approved by UK regulators as … Read more
Health Canada has green lit a drug previously approved for schizophrenia and depression to treat symptoms of agitation in Alzheimer’s patients. Rexulti (brexpiprazole) oral tablets manufactured by Otsuka Pharmaceutical Canada Inc. and Lundbeck Canada Inc. were issued a Notice of Compliance by the regulator, according to a company release Wednesday. This approval was given after … Read more
